Proposed LCD DL34356: Erythropoiesis Stimulating Agents (ESA) — CGS
Policy LCD-DL34356 · Oncology
Review proposed LCD on ESAs before July 4, 2026.
Code intelligence
Q4081 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code Q4081.
Critical code riskView HCPCS detail
Signal breakdown
4 shown · 4 total in platform
Risk: Critical
1
Critical
25%
1
High
25%
1
Routine
25%
1
Low
25%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Critical
Proposed LCD DL40334: Erythropoiesis Stimulating Agents — NGS
Policy LCD-DL40334 · Hematology
New LCD could affect reimbursement for anemia treatments.
LCD L34356: Erythropoiesis Stimulating Agents (ESA) — CGS
Policy LCD-L34356 · Hematology
New LCD for ESAs effective 03/05/2026.
LCD L40334: Erythropoiesis Stimulating Agents — NGS
Policy LCD-L40334 · ESRD
NGS ESA LCD goes live 7/15/2026 — review Hgb thresholds & docs now.
Audit documentation
Building an audit file that includes Q4081?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription